From Discovery to Production of Active Biotherapeutic and Pharmaceutical Ingredients
Jun 19 2018 Read 1216 Times
Kromasil fits across the entire biotherapeutic and pharmaceutical organisations. Typically, researchers carry out method development using Kromasil UHPLC and HPLC columns based on 1.8 - 5 μm particle sizes. Then scientists and engineers in discovery, process and manufacturing departments scale the method up according to their needs using the same Kromasil stationary phases in prepacked columns and bulk ranging from 7 to 25 μm. This Kromasil capability to supply the entire development and production path of an API is unique in the market and shortens the timeline plus minimises costs when producing a drug. With 30 years of experience, Kromasil continues to expand its list of products, provides ready-made columns as well as bulk material for normal phase, reversed phase, chiral, HILIC, SFC and SMB chromatography.
For more information go to www.kromasil.com.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Editon Articles - More than One Way to Hit the Bullseye - Gas Chromatography - Vacuum Ultraviolet Spectroscopy - News Bites from the UK Laboratory Industry Mass Spectrometry & Sp...
View all digital editions
Jun 26 2019 Basel, Switzerland
Jul 01 2019 Manchester, UK
Jul 03 2019 Tokyo, Japan
Jul 07 2019 Baltimore, MD, USA
Jul 09 2019 Johannesburg, South Africa